Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1991/006441external-prioritypatent/WO1992004462A1/en
Application filed by Immulogic Pharma Corp, New England Medical Center IncfiledCriticalImmulogic Pharma Corp
Publication of NO930820D0publicationCriticalpatent/NO930820D0/en
Publication of NO930820LpublicationCriticalpatent/NO930820L/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
Fremgangsmåte beskrives for behandling av en pasient infisert med en intracellulær patogen, hvilket omfatter til- førsel til pasienten av en intracellulær patogen-spesifikk, cytotoksisk T lymfocyt-stimulerend-2 antigen, eller et preparat av pasientens lymfocyter anriket for intracellulære patogen- spesif ikke cytotoksiske T lymofocyter.A method is described for treating a patient infected with an intracellular pathogen, which comprises administering to the patient an intracellular pathogen-specific, cytotoxic T lymphocyte-stimulating-2 antigen, or a preparation of the patient's lymphocytes enriched for intracellular pathogen-specific non-cytotoxic. T lymphocytes.
Therapeutic application of chimeric and radiotracer labelled antibodies, directed against the differentation antigen limited to human lymphocytes b, for treating lymphoma from lymphocytes b